| Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab (NCT04266730) | UNC Lineberger Comprehensive Cancer Center | 2027-05-20 |
| A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. (NCT07623642) | GV20 Therapeutics | 2026-06-02 |
| 5-Fluorouracil Response and Optimization STudy (The FROST Trial) (NCT07419464) | Washington University School of Medicine | 2026-04-21 |
| A Study Investigating the Efficacy and Safety of the Combination of Iparomlimab and Tuvonralimab With or Without Chemotherapy in Second-line and Subsequent Treatments for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (NCT07546383) | The Second Affiliated Hospital of Hainan Medical University | 2026-04-13 |
| Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas (NCT07455032) | Fox Chase Cancer Center | 2026-04-08 |
| Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC (NCT07509099) | Ji Dongmei | 2026-04-01 |
| Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC (NCT07400094) | National Medical Research Radiological Centre of the Ministry of Health of Russia | 2026-02-01 |
| A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (NCT07219212) | Johnson & Johnson Enterprise Innovation Inc. | 2026-01-26 |
| A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer (NCT07276399) | Janssen Research & Development, LLC | 2025-12-03 |
| Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors (NCT07151040) | One-carbon Therapeutics AB | 2025-08-22 |
| A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) (NCT07063212) | Memorial Sloan Kettering Cancer Center | 2025-07-02 |
| Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck (NCT05845307) | M.D. Anderson Cancer Center | 2025-06-20 |
| The Efficacy and Safety of Pucotenlimab Combined With TP Chemotherapy as Neoadjuvant Therapy for Locally Advanced HNSCC (NCT06895369) | Sir Run Run Shaw Hospital | 2025-05-01 |
| HN-BIO 02: A Phase II Randomized Study of the Effects of Delayed Elective Radiotherapy on Head and Neck MRI and Immune Response Biomarkers (NCT06487403) | University Health Network, Toronto | 2025-04-17 |
| Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck (NCT06744296) | Massachusetts Eye and Ear Infirmary | 2025-02-03 |
| Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma (Neo-ICT) (NCT06647563) | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 2024-11-01 |
| A Study of DM005 in Patients With Advanced Solid Tumors (NCT06515990) | Doma Biopharmaceutical（Suzhou）Co., Ltd. | 2024-10-31 |
| Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas (NCT06557889) | Institut Claudius Regaud | 2024-10-21 |
| Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma (NCT06606028) | University of California, San Francisco | 2024-10-09 |
| 2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma (NCT06492460) | Sun Yat-sen University | 2024-09-20 |
| A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors (NCT06549816) | Seagen, a wholly owned subsidiary of Pfizer | 2024-08-21 |
| Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study (NCT06534762) | Zhejiang Provincial People's Hospital | 2024-07-15 |
| A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer (NCT06380816) | Cancer Research UK | 2024-07-09 |
| A Phase 1b Study of WU-NK-101 in Combination With Cetuximab (NCT05674526) | Allotera Therapeutics | 2024-05-21 |
| A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer (NCT06385080) | Janssen Research & Development, LLC | 2024-04-22 |
| European Larynx Organ Preservation Study (ELOS) [MK-3475-C44] (NCT06137378) | University of Leipzig | 2024-04-17 |
| TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC (NCT06236425) | H. Lee Moffitt Cancer Center and Research Institute | 2024-03-14 |
| A Study of MGC026 in Participants With Advanced Solid Tumors (NCT06242470) | MacroGenics | 2024-03-06 |
| App-based Recording and Optimization of the Nutritional Status in Patients With Head and Neck Tumors During and After Radio(Chemo)Therapy (NCT06367257) | University of Erlangen-Nürnberg Medical School | 2024-02-29 |
| Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence (NCT05952934) | University of Arkansas | 2024-02-12 |
| Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN (NCT05743270) | Replimune, Inc. | 2024-01-30 |
| A Study of Head and Neck MRI and Tumor Microenvironment Biomarkers (NCT06085781) | University Health Network, Toronto | 2024-01-29 |
| Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer (NCT06110195) | University of Chicago | 2024-01-24 |
| A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers (NCT04892875) | Jennifer Choe | 2023-12-31 |
| Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors (NCT05280314) | IO Biotech | 2023-12-21 |
| Intraoperative Assessment of Surgical Margins Using Confocal Microscopy in Comparison With Reference Extemporaneous Examination (NCT05935995) | Institut de Cancérologie de Lorraine | 2023-11-28 |
| Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma (NCT06046482) | M.D. Anderson Cancer Center | 2023-11-28 |
| Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types (NCT06034860) | Molecular Templates, Inc. | 2023-11-01 |
| PABLIXIMAB as Neoadjuvant Therapy for Head and Neck Squamous-cell Carcinoma (NCT06125223) | Xijing Hospital | 2023-11-01 |
| Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers (NCT05553782) | Brigham and Women's Hospital | 2023-11-01 |
| Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) (NCT06022757) | Evopoint Biosciences Inc. | 2023-09-20 |
| Toripalimab in Combined With Cetuximab，Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC (NCT06081582) | First Affiliated Hospital of Zhejiang University | 2023-07-06 |
| Pilot Study of Imatinib Cetuximab Combo for H & N Cancer (NCT05816785) | University of Wisconsin, Madison | 2023-04-18 |
| A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors (NCT05462873) | Novartis Pharmaceuticals | 2023-04-04 |
| A Standardized Intervention to Improve the Management of Chemotherapy-induced Nausea and Vomiting (NCT05792228) | Tianjin Medical University Cancer Institute and Hospital | 2023-04-02 |
| Single-Arm Exploratory Study of PD-L1 Antibody Plus Neoadjuvant Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma (NCT07055841) | Xiuping Ding | 2023-04-01 |
| 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC (NCT05317000) | Barbara Burtness | 2023-03-23 |
| Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients (NCT05673577) | Fudan University | 2023-03-22 |
| A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma (NCT05668858) | Sichuan Baili Pharmaceutical Co., Ltd. | 2023-02-10 |
| A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours (NCT05605522) | 3B Pharmaceuticals GmbH | 2023-02-07 |
| A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors (NCT05653882) | Asher Biotherapeutics, Inc. | 2023-01-04 |
| A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (NCT05271604) | BioAtla, Inc. | 2022-12-13 |
| A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers (NCT05544929) | Novartis Pharmaceuticals | 2022-10-26 |
| Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer (NCT05620134) | Salubris Biotherapeutics Inc | 2022-10-17 |
| Pembrolizumab Plus Olaparib in LA-HNSCC (NCT05366166) | UNC Lineberger Comprehensive Cancer Center | 2022-09-02 |
| Prognostic Counselling in Palliative Head and Neck Cancer (ProCoPall) (NCT06699316) | Erasmus Medical Center | 2022-09-01 |
| Quantifying Systemic Immunosuppression to Personalize Cancer Therapy (NCT04941365) | Institut du Cancer de Montpellier - Val d'Aurelle | 2022-07-07 |
| Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy for HPV Negative Resectable Locally Advanced HNSCC (NCT05459415) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2022-06-22 |
| Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors (NCT05311618) | NGM Biopharmaceuticals, Inc | 2022-05-11 |
| A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) (NCT05323656) | Calliditas Therapeutics Suisse SA | 2022-04-06 |
| Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors (NCT05215574) | NGM Biopharmaceuticals, Inc | 2022-03-31 |
| Quantifying Systemic Immunosuppression to Personalize Cancer Therapy (NCT05621837) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2022-03-10 |
| A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With Head and Neck (SCCHN) (NCT05027204) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2022-03-04 |
| A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors (NCT05234606) | Silverback Therapeutics | 2022-03-01 |
| Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region (NCT05482880) | Maastricht University Medical Center | 2022-02-28 |
| A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) (NCT05121948) | HiberCell, Inc. | 2022-02-23 |
| ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer (NCT05182866) | Rakuten Medical, Inc. | 2022-01-21 |
| Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid (NCT05578820) | Gene Surgery LLC | 2022-01-01 |
| Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers (NCT04747054) | UNICANCER | 2021-12-01 |
| Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers (NCT05099549) | NKGen Biotech, Inc. | 2021-11-03 |
| Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC (NCT05053737) | University of Colorado, Denver | 2021-11-02 |
| Needs and Preferences of Patients With Head-neck Cutaneous SCC (NCT06046625) | Maastricht University Medical Center | 2021-11-01 |
| A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204) (NCT05061420) | Sanofi | 2021-10-08 |
| Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN (NCT04939480) | University Hospital, Essen | 2021-10-06 |
| MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) (NCT05007106) | Merck Sharp & Dohme LLC | 2021-09-16 |
| A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers (NCT04879849) | Takeda | 2021-09-09 |
| A Beta-only IL-2 ImmunoTherapY Study (NCT05086692) | Medicenna Therapeutics, Inc. | 2021-08-27 |
| Dose De-escalation and Sentinel LN Mapping Driven Radiotherapy of Contralateral Neck in Ipsilateral Node Positive HNSCC (NCT04688528) | Universitaire Ziekenhuizen KU Leuven | 2021-06-10 |
| Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies (NCT04913337) | NGM Biopharmaceuticals, Inc | 2021-06-09 |
| A Study to Assess Safety of Nivolumab in Routine Oncology Practice in China (NCT04825873) | Bristol-Myers Squibb | 2021-05-28 |
| Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 (NCT04795713) | Molecular Templates, Inc. | 2021-05-27 |
| A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors (NCT04895709) | Bristol-Myers Squibb | 2021-05-27 |
| Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM) (NCT04801472) | Institut de cancérologie Strasbourg Europe | 2021-05-07 |
| SHR-1701 in Patients With Recurrent/Metastatic Scchn (NCT04650633) | Jiangsu HengRui Medicine Co., Ltd. | 2021-05-07 |
| Sleep Apnea in Head and Neck Cancer Patients at the University of Colorado (NCT04922112) | University of Colorado, Denver | 2021-04-20 |
| Concurent Chemoradiotherapy in Head and Neck Cancers (NCT04780750) | Assiut University | 2021-04-01 |
| A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck (NCT04665843) | Hoffmann-La Roche | 2021-03-02 |
| Non Elective Vulnerable Elderly Radiotherapy (NCT04832555) | Azienda Ospedaliero Universitaria Policlinico Modena | 2021-02-20 |
| Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma (NCT04428047) | UNICANCER | 2021-02-04 |
| INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors (NCT04580485) | Incyte Corporation | 2021-02-03 |
| Using MASL to Combat Oral Cancer (NCT04188665) | Rowan University | 2021-01-29 |
| CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (NCT04633278) | Regeneron Pharmaceuticals | 2021-01-21 |
| A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation (NCT04262388) | University Health Network, Toronto | 2021-01-01 |
| Albumin-bound Paclitaxel Combined With Cisplatin Versus Docetaxel Combined With Cisplatin Induced Chemotherapy in Advanced Head and Neck Squamous Tummor (NCT04766827) | Tianjin Medical University Cancer Institute and Hospital | 2020-12-12 |
| Optimised Early Management of Squamous Cell Carcinoma of the Head and Neck Cancer (NCT04528420) | Centre Henri Becquerel | 2020-11-26 |
| TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy (NCT04596033) | Genocea Biosciences, Inc. | 2020-11-11 |
| A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10) (NCT04489888) | Merck Sharp & Dohme LLC | 2020-10-27 |
| GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy (NCT04601402) | Genome & Company | 2020-10-26 |
| Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies (NCT04465487) | Regeneron Pharmaceuticals | 2020-10-05 |
| A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers (NCT04260802) | Ocellaris Pharma, Inc. | 2020-09-24 |